Granisetrón Altan

Granisetrón Altan is a prescription medication that contains the active ingredient granisetron, a selective 5‑HT3 receptor antagonist, supplied for intravenous administration. It is marketed in the European Union and is used as an antiemetic to help prevent and treat nausea and vomiting associated with chemotherapy and postoperative settings. The product’s specific strength and formulation details are defined by the manufacturer according to regulatory guidelines and clinical practice.

Granisetrón Altan is indicated for the prevention and treatment of nausea and vomiting in specific clinical situations.

- Prevention of chemotherapy‑induced nausea and vomiting (CINV) in adult patients receiving moderately to highly emetogenic regimens. - Treatment of acute and delayed CINV when oral antiemetics are insufficient or not tolerated. - Prevention of postoperative nausea and vomiting (PONV) following surgical procedures requiring general anesthesia. - Adjunct therapy in patients undergoing radiotherapy where nausea is anticipated.

The safety profile of Granisetrón Altan includes a range of observed adverse events, most of which are mild to moderate in intensity.

Common: - Headache - Constipation - Diarrhea - Fatigue - Dizziness

Serious: - Severe allergic reaction (anaphylaxis) - Cardiac arrhythmia - Prolonged QT interval - Serotonin syndrome (when combined with serotonergic agents)

Before initiating Granisetrón Altan, clinicians should evaluate patient history and consider specific safety considerations.

- Assess for known hypersensitivity to granisetron or other 5‑HT3 antagonists. - Use caution in patients with a history of cardiac conduction disorders or prolonged QT interval. - Evaluate renal and hepatic function, as dose adjustments may be required in severe impairment. - Monitor for signs of serotonin syndrome if the patient is receiving serotonergic medications. - Consider pregnancy and lactation status; safety data are limited.

Granisetrón Altan may interact with other medicines, influencing its efficacy or safety profile.

Avoid: - Concurrent use with other 5‑HT3 antagonists, which can increase the risk of cardiac effects. - Combination with potent CYP3A4 inhibitors (e.g., ketoconazole) that may raise granisetron plasma levels.

Use with caution: - Serotonergic agents such as SSRIs, SNRIs, or triptans, due to potential serotonin syndrome. - Drugs that prolong QT interval (e.g., certain antiarrhythmics, antipsychotics). - Anesthetic agents that may affect cardiac rhythm when used together.